Navigation Links
Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
Date:8/3/2009

ARDEE, Ireland, Aug. 3 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today that it has received two Paragraph IV Certification Notices from Lupin Ltd. ("Lupin"). The Paragraph IV Certification Notices advise the Company of the filing of Abbreviated New Drug Applications (ANDAs) by Lupin for generic versions of the Company's oral contraceptives, LOESTRIN 24 FE and FEMCON FE.

LOESTRIN 24 FE, which was launched in March of 2006, is protected by U.S. Patent No. 5,552,394 which expires in 2014. FEMCON FE, which was introduced by the Company during the second half of 2006, is protected by U.S. Patent No. 6,667,050 which expires in 2019.

The Company is currently reviewing the detail of the Paragraph IV Certification Notices from Lupin and continues to have full confidence in its intellectual property protecting LOESTRIN 24 FE and FEMCON FE.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2008, as amended; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott Announces Earnings Release Date and Conference Call For Second Quarter 2009 Financial Results
2. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
3. Warner Chilcott to Present at Wachovias 19th Annual Mid-Year Equity Conference
4. Senators Webb and Warner Vote to Protect Americas Kids From Tobacco
5. Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference
6. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
7. Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
8. Warner Chilcott Proposes Redomestication From Bermuda to Ireland
9. Warner Chilcott to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
11. HBO, Warner Bros. Employee Initiatives and the Alzheimers Association, California Southland Chapter Present a Free, Public, Advance Screening of THE ALZHEIMERS PROJECT: Caregivers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: